Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunrise Technologies International, Inc

This article was originally published in The Gray Sheet

Executive Summary

Advises shareholders to reject an unsolicited tender offer for up to 2.3 mil. shares at $12.50 each from Growth Capital Corp. The offer covers about 5% of Sunrise's approximately 45.7 mil. shares outstanding. "The price is inadequate and shareholders have no withdrawal rights," Sunrise warns Dec. 14. "Tenders of shares made pursuant to the offer are irrevocable, even if the offer is extended," leaving open the possibility that payment could be delayed indefinitely and shareholders would have no ability to liquidate their investment, Sunrise notes. The company's Hyperion LTK Holmium laser system for treatment of hyperopia is slated for its second review by FDA's Ophthalmic Devices Panel at its Jan. 13-14 meeting. The panel deemed the device not approvable in July, citing deficient long-term data (1"The Gray Sheet" July 26, p. 3). Additional data have since been submitted in support of the firm's premarket approval application covering reduction of hyperopia of +0.75 to +2.50 diopters

You may also be interested in...



Deficient Long-Term Data Render Sunrise Hyperopia Tool Not Approvable

Forty-six percent of the eyes treated with Sunrise Technologies' Hyperion laser thermal keratomileusis (LTK) system for hyperopia in clinical trials were under-corrected by greater than 1.00 diopter twenty-four months post-treatment, data contained in the firm's premarket approval application showed.

Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.

Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit

US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel